Table 1.
Cohort | ARISTOTLE | RE-LY |
---|---|---|
Patients | n = 3999 | n = 1088 |
Age, (years) median (IQR) | 70.0 (63.0–76.0) | 72.0 (67.0–77.0) |
Sex: male | 63.0% (2519) | 62.8% (683) |
Body mass index, kg/m2 | 28.6 (25.4–32.7) [19] | 27.9 (24.9–31.2) [2] |
Current smoker | 8.8% (353) | 7.5% (82) |
Diabetes | 25.0% (998) | 21.1% (230) |
Hypertension | 87.7% (3506) | 79.0% (859) |
Congestive heart failure | 31.2% (1247) | 29.1% (317) |
Prior myocardial infarction | 13.0% (518) | 16.8% (183) |
Prior peripheral arterial disease | 4.8% (193) | 3.6% (39) |
Prior stroke/TIA | 18.4% (736) | 20.3% (221) |
Medications | ||
Prior beta-blocker | 66.5% (2660) | 61.4% (668) |
Prior aspirin | 41.7% (1667) | 40.5% (441) |
Prior alopidogrel | 3.9% (154) | 5.0% (54) |
Prior statin | 41.3% (1652) | 42.2% (459) |
Prior ACE inhibitor | 50.9% (2036) | 49.9% (543) |
Prior ARB | 23.8% (952) | 21.2% (231) |
Prior ACE inhibitor or ARB | 71.6% (2864) | 68.5% (745) |
Prior amiodarone | 13.5% (538) | 12.9% (140) |
Biomarkers | ||
NT-proBNP (ng/L) | 697.5 (368.0–1248.8) [3] | 845.5 (391.8–1470.0) [0] |
hs-cTnT (ng/L) | 10.8 (7.4–16.6) | 12.1 (7.7–19.5) |
GDF-15 (ng/L) | 1371.0 (966.0–2060.0) | 1474.5 (1097.5–2147.5) |
CRP (mg/L) | 2.2 (1.0–4.6) [4] | 2.5 (1.2–5.5) [357] |
IL-6 (ng/L) | 2.3 (1.5–4.0) [1] | 2.4 (1.5–3.9) [358] |
eGFR (CKD-EPI) (mL/min) | 56.3 (45.5–68.6) [1] | 65.7 (54.9–76.9) [9] |
Cystatin C (mg/L) | 1.0 (0.8–1.2) [4] | 1.0 (0.8–1.2) [357] |
D-dimer (μg/L) | 521.0 (332.0–859.0) [26] | 511.5 (322.2–888.0) [358] |
Soluble ACE2 (sACE2) (NPX) | 3.9 (3.5–4.4) | 4.4 (3.9–4.8) |
TIA, transient ischaemic attack; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; NT-proBNP, N-terminal probrain natriuretic peptide; hs-cTnT, high-sensitive cardiac troponin T; GDF-15, growth differentiation factor 15; CRP, C-reactive protein; IL-6, interleukin-6; eGFR, estimated glomerular filtration rate; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration.
Numbers in square brackets represent missing data.